Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2012

Open Access 01-12-2012 | Primary research

Inhibition of breast cancer cell proliferation in repeated and non-repeated treatment with zoledronic acid

Authors: Toni Ibrahim, Laura Mercatali, Emanuele Sacanna, Anna Tesei, Silvia Carloni, Paola Ulivi, Chiara Liverani, Francesco Fabbri, Michele Zanoni, Wainer Zoli, Dino Amadori

Published in: Cancer Cell International | Issue 1/2012

Login to get access

Abstract

Background

Zoledronic acid is used to treat bone metastases and has been shown to reduce skeletal-related events and exert antitumor activity. The present in vitro study investigates the mechanism of action of Zoledronic Acid on breast cancer cell lines with different hormonal and HER2 patterns. Furthermore, we investigated the efficacy of repeated versus non-repeated treatments.

Methods

The study was performed on 4 breast cancer cell lines (BRC-230, SkBr3, MCF-7 and MDA-MB-231). Non-repeated treatment (single exposure of 168 hrs’ duration) with zoledronic acid was compared with repeated treatment (separate exposures, each of 48 hrs’ duration, for a total of 168 hrs) at different dosages. A dose–response profile was generated using sulforhodamine B assay. Apoptosis was evaluated by TUNEL assay and biomolecular characteristics were analyzed by western blot.

Results

Zoledronic acid produced a dose-dependent inhibition of proliferation in all cell lines. Anti-proliferative activity was enhanced with the repeated treatment, proving to be statistically significant in the triple-negative lines. In these lines repeated treatment showed a cytocidal effect, with apoptotic cell death caused by caspase 3, 8 and 9 activation and decreased RAS and pMAPK expression. Apoptosis was not observed in estrogen receptor-positive line: p21 overexpression suggested a slowing down of cell cycle. A decrease in RAS and pMAPK expression was seen in HER2-overexpressing line after treatment.

Conclusions

The study suggests that zoledronic acid has an antitumor activity in breast cancer cell lines. Its mechanism of action involves the decrease of RAS and RHO, as in osteoclasts. Repeated treatment enhances antitumor activity compared to non-repeated treatment. Repeated treatment has a killing effect on triple-negative lines due to apoptosis activation. Further research is warranted especially in the treatment of triple-negative breast cancer.
Appendix
Available only for authorised users
Literature
1.
Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: Cancer statistics, 2007. CA Cancer J Clin. 2007, 57 (1): 43-66. 10.3322/canjclin.57.1.43.CrossRefPubMed
2.
Coleman RE: Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006, 12 (20 Pt 2): 6243s-6249s.CrossRefPubMed
3.
Mercatali L, Ibrahim T, Sacanna E, Flamini E, Scarpi E, Calistri D, Ricci M, Serra P, Ricci R, Zoli W, Kang Y, Amadori D: Bone metastases detection by circulating biomarkers: OPG and RANK-L. Int J Oncol. 2011, 39 (1): 255-261.PubMed
4.
Sacanna E, Ibrahim T, Gaudio M, Mercatali L, Scarpi E, Zoli W, Serra P, Bravaccini S, Ricci R, Serra L, Amadori D: The role of CXCR4 in the prediction of bone metastases from breast cancer: a pilot study. Oncology. 2011, 80 (3–4): 225-231.CrossRefPubMed
5.
Martin TJ, Moseley JM: Mechanisms in the skeletal complications of breast cancer. Endocr Relat Cancer. 2000, 7 (4): 271-284. 10.1677/erc.0.0070271.CrossRefPubMed
6.
Ibrahim T, Flamini E, Fabbri L, Serra P, Mercatali L, Ricci R, Sacanna E, Falasconi MC, Casadei R, Galassi R, Giannini M, Bazzocchi O, Calzolari F, Nunziatini R, Gaudio M, Maltoni M, Amadori D: Multidisciplinary approach to the treatment of bone metastases: Osteo-Oncology Center, a new organizational model. Tumori. 2009, 95 (3): 291-297.PubMed
7.
Coleman RE: Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev. 2001, 27 (3): 165-176. 10.1053/ctrv.2000.0210.CrossRefPubMed
8.
Mountzios G, Dimopoulos MA, Bamias A, Papadopoulos G, Kastritis E, Syrigos K, Pavlakis G, Terpos E: Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton. Acta Oncol. 2007, 46 (2): 221-229. 10.1080/02841860600635870.CrossRefPubMed
9.
Ibrahim T, Flamini E, Mercatali L, Sacanna E, Serra P, Amadori D: Pathogenesis of osteoblastic bone metastases from prostate cancer. Cancer. 2010, 116 (6): 1406-1418. 10.1002/cncr.24896.CrossRefPubMed
10.
Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, Frith JC: Cellular and molecular mechanisms of action of bisphosphonates. Cancer. 2000, 88 (12 Suppl): 2961-2978.CrossRefPubMed
11.
Lipton A, Cook R, Saad F, Major P, Garnero P, Terpos E, Brown JE, Coleman RE: Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer. 2008, 113 (1): 193-201. 10.1002/cncr.23529.CrossRefPubMed
12.
Doggrell SA: Clinical efficacy and safety of zoledronic acid in prostate and breast cancer. Expert Rev Anticancer Ther. 2009, 9 (9): 1211-1218. 10.1586/era.09.95.CrossRefPubMed
13.
Costa L, Lipton A, Coleman RE: Role of bisphosphonates for the management of skeletal complications and bone pain from skeletal metastases. Support Cancer Ther. 2006, 3 (3): 143-153. 10.3816/SCT.2006.n.012.CrossRefPubMed
14.
Santini D, Virzi V, Fratto ME, Bertoldo F, Sabbatini R, Berardi R, Calipari N, Ottaviani D, Ibrahim T: Can we consider zoledronic acid a new antitumor agent? Recent evidence in clinical setting. Curr Cancer Drug Targets. 2010, 10 (1): 46-54. 10.2174/156800910790980223.CrossRefPubMed
15.
Guise TA: Antitumor effects of bisphosphonates: promising preclinical evidence. Cancer Treat Rev. 2008, 34 (Suppl 1): S19-S24.CrossRefPubMed
16.
Jagdev SP, Coleman RE, Shipman CM, Rostami HA, Croucher PI: The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer. 2001, 84 (8): 1126-1134. 10.1054/bjoc.2001.1727.PubMedCentralCrossRefPubMed
17.
van der Pluijm G, Vloedgraven H, van Beek E, van der Wee-Pals L, Lowik C, Papapoulos S: Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest. 1996, 98 (3): 698-705. 10.1172/JCI118841.PubMedCentralCrossRefPubMed
18.
Boissier S, Ferreras M, Peyruchaud O, Magnetto S, Ebetino FH, Colombel M, Delmas P, Delaisse JM, Clezardin P: Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res. 2000, 60 (11): 2949-2954.PubMed
19.
Wood J, Bonjean K, Ruetz S, Bellahcene A, Devy L, Foidart JM, Castronovo V, Green JR: Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther. 2002, 302 (3): 1055-1061. 10.1124/jpet.102.035295.CrossRefPubMed
20.
Santini D, Vincenzi B, Dicuonzo G, Avvisati G, Massacesi C, Battistoni F, Gavasci M, Rocci L, Tirindelli MC, Altomare V, Tocchini M, Bonsignori M, Tonini G: Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res. 2003, 9 (8): 2893-2897.PubMed
21.
Daubine F, Le Gall C, Gasser J, Green J, Clezardin P: Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J Natl Cancer Inst. 2007, 99 (4): 322-330. 10.1093/jnci/djk054.CrossRefPubMed
22.
Ottewell PD, Deux B, Monkkonen H, Cross S, Coleman RE, Clezardin P, Holen I: Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo. Clin Cancer Res. 2008, 14 (14): 4658-4666. 10.1158/1078-0432.CCR-07-1545.CrossRefPubMed
23.
Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Postlberger S, Menzel C, Jakesz R, Seifert M, Hubalek M, Bjelic-Radisic V, Samonigg H, Tausch C, Eidtmann H, Steger G, Kwasny W, Dubsky P, Fridrik M, Fitzal F, Stierer M, Rucklinger E, Greil R, Marth C: Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med. 2009, 360 (7): 679-691. 10.1056/NEJMoa0806285.CrossRefPubMed
24.
Coleman RE, Lipton A, Roodman GD, Guise TA, Boyce BF, Brufsky AM, Clezardin P, Croucher PI, Gralow JR, Hadji P, Holen I, Mundy GR, Smith MR, Suva LJ: Metastasis and bone loss: advancing treatment and prevention. Cancer Treat Rev. 2010, 36 (8): 615-620. 10.1016/j.ctrv.2010.04.003.PubMedCentralCrossRefPubMed
25.
Marra M, Abbruzzese A, Addeo R, Del Prete S, Tassone P, Tonini G, Tagliaferri P, Santini D, Caraglia M: Cutting the limits of aminobisphosphonates: new strategies for the potentiation of their anti-tumour effects. Curr Cancer Drug Targets. 2009, 9 (7): 791-800. 10.2174/156800909789760285.CrossRefPubMed
26.
Caraglia M, Marra M, Naviglio S, Botti G, Addeo R, Abbruzzese A: Zoledronic acid: an unending tale for an antiresorptive agent. Expert Opin Pharmacother. 2010, 11 (1): 141-154. 10.1517/14656560903485664.CrossRefPubMed
27.
Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR: Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007, 356 (18): 1809-1822. 10.1056/NEJMoa067312.CrossRefPubMed
28.
Hershman DL, McMahon DJ, Crew KD, Cremers S, Irani D, Cucchiara G, Brafman L, Shane E: Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol. 2008, 26 (29): 4739-4745. 10.1200/JCO.2008.16.4707.PubMedCentralCrossRefPubMed
29.
Santini D, Galluzzo S, Vincenzi B, Schiavon G, Fratto E, Pantano F, Tonini G: New developments of aminobisphosphonates: the double face of Janus. Ann Oncol. 2007, 18 (Suppl 6): vi164-vi167.PubMed
30.
Zhao X, Xu X, Guo L, Ragaz J, Guo H, Wu J, Shao Z, Zhu J, Guo X, Chen J, Zhu B, Wang Z, Hu X: Biomarker alterations with metronomic use of low-dose zoledronic acid for breast cancer patients with bone metastases and potential clinical significance. Breast Cancer Res Treat. 2010, 124 (3): 733-743. 10.1007/s10549-010-1183-6.CrossRefPubMed
31.
Amadori D, Bertoni L, Flamigni A, Savini S, De Giovanni C, Casanova S, De Paola F, Amadori A, Giulotto E, Zoli W: Establishment and characterization of a new cell line from primary human breast carcinoma. Breast Cancer Res Treat. 1993, 28 (3): 251-260. 10.1007/BF00666586.CrossRefPubMed
32.
Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR: New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst. 1990, 82 (13): 1107-1112. 10.1093/jnci/82.13.1107.CrossRefPubMed
33.
Caraglia M, Leardi A, Corradino S, Ciardiello F, Budillon A, Guarrasi R, Bianco AR, Tagliaferri P: Alpha-interferon potentiates epidermal growth factor receptor-mediated effects on human epidermoid carcinoma KB cells. Int J Cancer. 1995, 61 (3): 342-347. 10.1002/ijc.2910610312.CrossRefPubMed
34.
Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, Hose C, Langley J, Cronise P, Vaigro-Wolff A: Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst. 1991, 83 (11): 757-766. 10.1093/jnci/83.11.757.CrossRefPubMed
35.
Hahnel A, Wichmann H, Kappler M, Kotzsch M, Vordermark D, Taubert H, Bache M: Effects of osteopontin inhibition on radiosensitivity of MDA-MB-231 breast cancer cells. Radiat Oncol. 2010, 5: 82-10.1186/1748-717X-5-82.PubMedCentralCrossRefPubMed
36.
Lamberti A, Longo O, Marra M, Tagliaferri P, Bismuto E, Fiengo A, Viscomi C, Budillon A, Rapp UR, Wang E, Venuta S, Abbruzzese A, Arcari P, Caraglia M: C-Raf antagonizes apoptosis induced by IFN-alpha in human lung cancer cells by phosphorylation and increase of the intracellular content of elongation factor 1A. Cell Death Differ. 2007, 14 (5): 952-962.PubMed
37.
Marra M, Santini D, Meo G, Vincenzi B, Zappavigna S, Baldi A, Rosolowski M, Tonini G, Loeffler M, Lupu R, Addeo SR, Abbruzzese A, Budillon A, Caraglia M: Cyr61 downmodulation potentiates the anticancer effects of zoledronic acid in androgen-independent prostate cancer cells. Int J Cancer. 2009, 125 (9): 2004-2013. 10.1002/ijc.24648.CrossRefPubMed
38.
39.
Hatoum HT, Lin SJ, Smith MR, Barghout V, Lipton A: Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases: analysis of a national medical claims database. Cancer. 2008, 113 (6): 1438-1445. 10.1002/cncr.23775.PubMedCentralCrossRefPubMed
40.
Senaratne SG, Mansi JL, Colston KW: The bisphosphonate zoledronic acid impairs Ras membrane [correction of impairs membrane] localisation and induces cytochrome c release in breast cancer cells. Br J Cancer. 2002, 86 (9): 1479-1486. 10.1038/sj.bjc.6600297.PubMedCentralCrossRefPubMed
41.
Rachner TD, Singh SK, Schoppet M, Benad P, Bornhauser M, Ellenrieder V, Ebert R, Jakob F, Hofbauer LC: Zoledronic acid induces apoptosis and changes the TRAIL/OPG ratio in breast cancer cells. Cancer Lett. 2010, 287 (1): 109-116. 10.1016/j.canlet.2009.06.003.CrossRefPubMed
42.
43.
Fabbri F, Brigliadori G, Carloni S, Ulivi P, Vannini I, Tesei A, Silvestrini R, Amadori D, Zoli W: Zoledronic acid increases docetaxel cytotoxicity through pMEK and Mcl-1 inhibition in a hormone-sensitive prostate carcinoma cell line. J Transl Med. 2008, 6: 43-10.1186/1479-5876-6-43.PubMedCentralCrossRefPubMed
44.
Chen T, Berenson J, Vescio R, Swift R, Gilchick A, Goodin S, LoRusso P, Ma P, Ravera C, Deckert F, Schran H, Seaman J, Skerjanec A: Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol. 2002, 42 (11): 1228-1236. 10.1177/009127002762491316.CrossRefPubMed
45.
Caraglia M, Santini D, Marra M, Vincenzi B, Tonini G, Budillon A: Emerging anti-cancer molecular mechanisms of aminobisphosphonates. Endocr Relat Cancer. 2006, 13 (1): 7-26. 10.1677/erc.1.01094.CrossRefPubMed
46.
Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, Golub E, Rodan GA: Bisphosphonate action, Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest. 1991, 88 (6): 2095-2105. 10.1172/JCI115539.PubMedCentralCrossRefPubMed
47.
Salzano G, Marra M, Porru M, Zappavigna S, Abbruzzese A, La Rotonda MI, Leonetti C, Caraglia M, De Rosa G: Self-assembly nanoparticles for the delivery of bisphosphonates into tumors. Int J Pharm. 2011, 403 (1–2): 292-297.CrossRefPubMed
48.
Marra M, Salzano G, Leonetti C, Porru M, Franco R, Zappavigna S, Liguori G, Botti G, Chieffi P, Lamberti M, Vitale G, Abbruzzese A, La Rotonda MI, De Rosa G, Caraglia M: New self-assembly nanoparticles and stealth liposomes for the delivery of zoledronic acid: a comparative study. Biotechnol Adv. 2012, 30 (1): 302-309. 10.1016/j.biotechadv.2011.06.018.CrossRefPubMed
49.
Marra M, Salzano G, Leonetti C, Tassone P, Scarsella M, Zappavigna S, Calimeri T, Franco R, Liguori G, Cigliana G, Ascani R, La Rotonda MI, Abbruzzese A, Tagliaferri P, Caraglia M, De Rosa G: Nanotechnologies to use bisphosphonates as potent anticancer agents: the effects of zoledronic acid encapsulated into liposomes. Nanomedicine. 2011, 7 (6): 955-964. 10.1016/j.nano.2011.03.004.CrossRefPubMed
50.
Amin D, Cornell SA, Gustafson SK, Needle SJ, Ullrich JW, Bilder GE, Perrone MH: Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis. J Lipid Res. 1992, 33 (11): 1657-1663.PubMed
51.
van Beek E, Pieterman E, Cohen L, Lowik C, Papapoulos S: Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem Biophys Res Commun. 1999, 264 (1): 108-111. 10.1006/bbrc.1999.1499.CrossRefPubMed
52.
Coxon FP, Helfrich MH, Van't Hof R, Sebti S, Ralston SH, Hamilton A, Rogers MJ: Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. J Bone Miner Res. 2000, 15 (8): 1467-1476. 10.1359/jbmr.2000.15.8.1467.CrossRefPubMed
53.
Senaratne SG, Pirianov G, Mansi JL, Arnett TR, Colston KW: Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer. 2000, 82 (8): 1459-1468. 10.1054/bjoc.1999.1131.PubMedCentralCrossRefPubMed
54.
Busch M, Rave-Frank M, Hille A, Duhmke E: Influence of clodronate on breast cancer cells in vitro. Eur J Med Res. 1998, 3 (9): 427-431.PubMed
55.
Hu X, Stern HM, Ge L, O'Brien C, Haydu L, Honchell CD, Haverty PM, Peters BA, Wu TD, Amler LC, Chant J, Stokoe D, Lackner MR, Cavet G: Genetic alterations and oncogenic pathways associated with breast cancer subtypes. Mol Cancer Res. 2009, 7 (4): 511-522. 10.1158/1541-7786.MCR-08-0107.CrossRefPubMed
56.
Kobayashi S: Basal-like subtype of breast cancer: a review of its unique characteristics and their clinical significance. Breast Cancer. 2008, 15 (2): 153-158. 10.1007/s12282-008-0034-3.CrossRefPubMed
57.
Coleman RE, Winter MC, Cameron D, Bell R, Dodwell D, Keane MM, Gil M, Ritchie D, Passos-Coelho JL, Wheatley D, Burkinshaw R, Marshall SJ, Thorpe H: The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. Br J Cancer. 2010, 102 (7): 1099-1105. 10.1038/sj.bjc.6605604.PubMedCentralCrossRefPubMed
Metadata
Title
Inhibition of breast cancer cell proliferation in repeated and non-repeated treatment with zoledronic acid
Authors
Toni Ibrahim
Laura Mercatali
Emanuele Sacanna
Anna Tesei
Silvia Carloni
Paola Ulivi
Chiara Liverani
Francesco Fabbri
Michele Zanoni
Wainer Zoli
Dino Amadori
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2012
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/1475-2867-12-48

Other articles of this Issue 1/2012

Cancer Cell International 1/2012 Go to the issue

Primary research

Neuropeptide-inducible upregulation of proteasome activity precedes nuclear factor kappa B activation in androgen-independent prostate cancer cells

Review

Pathobiology of cancer metastasis: a short account

Primary research

The tumour metabolism inhibitors GSAO and PENAO react with cysteines 57 and 257 of mitochondrial adenine nucleotide translocase

Primary research

Investigation of the apoptotic way induced by digallic acid in human lymphoblastoid TK6 cells

Primary research

Lycorine induces cell-cycle arrest in the G0/G1 phase in K562 cells via HDAC inhibition

Primary research

Establishment and characterization of two human breast carcinoma cell lines by spontaneous immortalization: Discordance between Estrogen, Progesterone and HER2/neu receptors of breast carcinoma tissues with derived cell lines
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits